Emerging INSTI Resistance in East African HIV-1 Under the 2019 WHO DTG Rollout

Domaine:

healthcare

Type de record:

paper

Créateur:

Kel

Éditeur:

Cen

Éditeur:

OSF

Hôte:

Public HIV-1 drug-resistance surveillance derives per-drug Sierra levels from pol sequences without observed individual treatment history. Naive associations between mutation features and Sierra levels conflate causal drug pressure with subtype-specific polymorphism and non-random sampling. CausalPhylo v1 specifies a DAG-based identification framework and validates it on synthetic ground truth. This preregistration locks the real-data application against SAWA v0.1.0 in advance of running the analysis.

Kouyos-Group/DTG-resistance-MARISA

This repository contains the MARISA model version used in "Predicting emergent Dolutegravir resistan

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

Abstract Introduction A potential concern with the use of dapivirine (DPV) for HIV prevention is

Harnessing Enhanced Adherence Counseling to improve HIV-1 viral suppression rates among children on DTG-based regimens in Malawi

Are HIV Epidemics among Men Who Have Sex with Men Emerging in the Middle East and North Africa?: A Systematic Review and Data Synthesis

Background

Men who have sex with men (MSM) bear a disproportionately higher burden o

Performance and usability evaluation of the INSTI HIV self-test in Kenya for qualitative detection of antibodies to HIV

Drug Resistance Mutations Among South African Children Living With HIV on WHO-recommended ART Regimens

Abstract Background Children living with hu